4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

S-8 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

EFFECT - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

S-1 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

8-K/A - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

Advancing FDA-Cleared Phase IIa Parkinson's Program Targeting Neuroinflammation Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia™ JUPITER, FL, March 02, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that management will participate in the BIO Investment and Growth Summit 2026, hosted by the Biotechnology Innovation Organization (BIO), taking place March 2 to 3, 2026 in Miami Beach, Florida. The Company's corporate presentation is scheduled for March 2, 2026, at 2:30 PM. At BIO, Jupiter will discuss its FDA-cleare

JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, announces that members of senior management have been invited, as the only company this evening, to present its progress at a private investor dinner taking place Wednesday, February 25, 2026 at 6:00 PM ET at The Mar-a-Lago Club in Palm Beach, Florida. The invitation-only event will convene a select group of accredited and high net worth investors for focused discussions on emerging investment opportunities. The event is being organized by the Money Channel NYC. Jup

Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that it has entered into an Omnibus Amendment with YA II PN, Ltd. modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued under the Company's Standby Equity Purchase Agreement. Under the amendment: Monthly installment payments will now begin on April 1, 2026Principal repayments will follow a defined schedule agreed

Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ consumer longevity product line. This initiative reinforces Jupiter's dual-engine strategy, combining a clinical-stage pharmaceutical pipeline with a direct-to-consumer longevity business. As GLP-1 adoption accelerates globally, Jupiter se

Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to invite investors to a webinar on January 6, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Jupiter Neuroscience Chairman and CEO Chister Rosén who will provide investors with an overview of Jupiter Neurosciences' scientific platform, clinical development plans, and commercial strategy heading into 2026. Rosén will discuss the Company's lead asset, JOTROL™, including its differentiated bioavailability profile and upcom

Company advances JOTROL™ into Phase 2a Parkinson's trial, launches Nugevia™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the publication of a shareholder letter from Chairman and CEO Christer Rosén marking Jupiter's first full year as a public company and outlining the major achievements and strategic priorities propelling the Company into 2026. Dear Fellow Shareholders, As we celebrate our first full year as a public company, I want to express m

Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic platform targeting neuroinflammation and mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2a clinical trial of JOTROL™ in patients with Parkinson's disease. The FDA's clearance marks a significant regulatory milestone for Jupiter, enabling the Company to begin enrollment in its exploratory Phase 2a trial designed to evaluate the safety and tolerability of JOTROL in patients wi

Financing designed to support Phase 2 Parkinson's trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc ("JUNS" or the "Company") (NASDAQ:JUNS), a clinical stage biopharmaceutical company that is advancing a therapeutic pipeline targeting central nervous system ("CNS") disorders, while also expanding into the consumer longevity market with its Nugevia™ product line, today announced that it has entered into two strategic financing agreements with an affiliate of Yorkville Advisors Global, LP ("Yorkville"), providing JUNS with the potential to access up to $20 million in capital (the "Financing"), subject to certain cond

Partnership strengthens Nugevia™ launch bringing clinical and scientific integrity to the fast-growing longevity space Jupiter, Florida, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that Jean Fallacara, visionary entrepreneur, neuroscientist, and internationally recognized biohacker, has joined the Company as the third official brand ambassador for Nugevia™, Jupiter Neurosciences' new consumer longevity supplement line. Visionary entrepreneur and biohacker Jean Fallacara named Nugevia™ brand ambassador Fallacara, known globally for pioneering advances in biohacking, biotechnology, and human performance, has earned recognition as one of

Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company pioneering therapies for central nervous system (CNS) disorders and advancing science-based consumer health solutions, today announced a pivotal expansion of its dual-path business model with the launch of its dedicated Nugevia™ e-commerce website, www.nugevia.com, and the opening of pre-orders for its first three nutraceutical supplements: Nugevia™ GLO, Nugevia™ PWR, and Nugevia™ MND. The products are available for purchase via subscription or as a one-time order, with shipp